News - TherapySelect

There are 2 new features, which make the PCDx test even better: As of now it is possible to perform an IHC (immunohistochemistry) for PD-L1 with the clone SP142. PD-L1 SP142 is the companion diagnostic for the immune-checkpoint-inhbitor Atezolizumab. Atezolizumab is applied in breast cancer, non-...

From November 27th till 29th we participated in the EIT Health Pop-Up Incubator Series in Erlangen. On three days we received information on upcoming funding programs of EIT Health and how to apply for them. In addition we got a social media training and information regarding the new Medical Device...

On November 14th 2019 we joined the Future X Healthcare in Munich. The focus of this event was the new role of patients in the digital area. Questions were discussed like how can patient data responsibly be used for research or how can digital innovations improve treatments. Furthermore companies...

On October 22nd 2019 TherapySelect took place in the Partners4Patients event here in Heidelberg. We and other startups spent an afternoon to talk to health insurances. The aim was to discuss the integration of innovations from the digital health sector in the services of the health insurances...

On the 19 th and 20 th of September 2019 we joined the Healthcare Demo Day and Final Event of Innolabs in Oslo. The idea of the Healthcare Demo Day was that the best healthcare innovators can meet investors as well as potential customers. Within the Final Event of Innolabs we presented the results...

TherapySelect took part at the fair MedtecLIVE, as well as at the medical technology congress MedTech Summit from May 21 to 23 in Nuremberg. Thus, we were part of overall 402 exhibitors and had the chance to present our innovative services and products to nearly 4.600 professional visitors. MedTech...

TherapySelect was one of the 20 companies, who were selected out of all applicants, to take part at the Boot Camp 2018 in Brussels. From November 12 to 13, 2018 the training programme by EUREKA and Helsinki's Hanken School of Economics for a scale-up of the companies took place. Content on...

Through different GoGlobal programmes by EIT Health, the international expansion of small and medium entrepreneurs gets supported. From October 25 to November 2, 2018 TherapySelect took part at the programme 'Market Access in China'. Visiting innovative metropolises and companies in China, a...

Xi'an is considered to be an innovation metropolis of central-west-China. The start-up competition aims to link this region with international companies. We were invited as one out of 20 companies, to convince the jury with our project on October 18, 2018 in Hamburg. Dr. Frank Kischkel presented in...

The SHIP-Event (short for „ Ship for Health Innovation Pitches“ ) is a competition for start-up s hosted by EIT Health Germany. It takes place during a cruise on the river Neckar. Aboard the „Königin Silvia“, 28 innovative companies went all out while presenting their projects. One of them was...

On April 18 and 19, 2018 the seventh innovative congress PerMediCon took place in Cologne. The 500 visitors could exchange interesting content under the topic „Genomic Medicine – Understand, Develop and Implement together“. TherapySelect presented the digital project „Disease Management Platform“,...

Dear Reader, within this newsletter we would like to inform you about the grants and awards, which TherapySelect and its cooperation partners received this year, as well as about further news. Grants of TherapySelect We are very pleased that we received a grant from the EIT Health Headstart...

Dear Reader, We are glad to inform you that we could publish research findings about our diagnostic CTR-Test® (Chemotherapy Resistance Test) within two publications this year: The first publication entitled “New in vitro system to predict chemotherapeutic efficacy of drug combinations in fresh...

Dear Reader, to further improve cancer patient care we are pleased to inform you that we are now able to offer exclusively an efficacy test based on the analysis of molecular-based biomarker for targeted drugs (including anti-hormone-drugs and immunotherapies) and chemotherapeutics. After careful...

Dear Reader, for the further improvement of patient care we are pleased to inform you that we are now able to offer a Liquid Biopsy for cancer therapy planning and monitoring as well as the possibility of tumor cell storage. Guardant360 ® The analysis of the Liquid Biopsy Guardant360 ® is performed...

Caris Molecular Intelligence ® Tumor Profiling from Caris Life Sciences for Optimzing Cancer Therapy is now Offered by TherapySelect in Germany Dear Reader, We are glad to inform you that we now offer an evaluation of effectiveness of targeted and selected chemotherapeutic drugs...

Personal Invitation to the Free Caris Symposium Concerning Therapy Optimization by CMI Diagnostics on 26.09.2015 in the Framework of the European Cancer Congress (ECCO) in Vienna Dear Reader, We are glad to invite you to the Caris Life Sciences CMI Symposium in the framework of...

Dear Reader, we are delighted to announce that since March 8th our new website has been online. The most important features are listed below: The website was completely redesigned. Now you can find information about our company and about our diagnostic services quickly and efficiently. Beside the...

<>For supporting the international business operation, it was necessary to provide multilingual information. Therefore the web page was revised and composed with appropriate new technologies. We hope this web page provides all important information in an easy and understandable way. In the...

CEIC is a German company which will distribute the CTR-Test ® and the Oncompass™ Service throughout the world. The cooperation is officially starting this month. Official website from CEIC

<>Smart Therapy Select is a Lebanese company distributing the CTR-Test ® exclusively in Lebanon. The cooperation is officially starting this month.

In April 2014 the Mayo Clinic, which is a worldwide leader in medical care, research and education, started to scan specific regions by Next-Generation Sequencing in 50 genes known to affect tumor growth for each cancer patients at their clinics. The other nonprofit Institute, Dana-Farber Cancer...

The DKFZ was founded in 1964. For the 50 years in business celebration, an anniversary issue was released containing a list of the 20 most cited publications which were published by the DKFZ within this period of time. These publications include two articles, which were written by Dr. Frank...

For further improvement of the CTR-Tests ® , the BMWi granted a funding for TherapySelect. In particular the number of drugs testable with the testing system will be increased within this project.

The BIOPRO releases an article about TherapySelect in the section "Biotechnologie & Pharma, Medizintehcnik, Diagnostick, Ernährung". The article is available online. Link to the online article "TherapySelect – identifying susceptibility to cancer therapy"...

<>As in the previous year, TherapySelect attends an important conference concerning personalized medicine for exchanging news about developments and progress in this field.

<>The principal investigator Prof. Sehouli (Charité Berlin) officially finished the recruitment of patients for the Predictor-Study. The aim, to recruit 100 female patients for the assessment of the diagnostic, is achieved. 123 tumor samples from primary disease were sent in. 9 samples were...

&lt;&gt;Due to significant additional expenses within the Predictor-Study, the funding of the project sponsor Jülich is officially extended for additional six months.

<>KPS and TherapySelect applied for a corporate development project which is authorized by the European Union. The project is named ONCOLINE (Oncological Decision Support System) and is an official EUREKA project. It aims to improve the personalized medication in oncology.

The Deutsche Welle publishes an online article about "coustom-fit cancer treatment". The article contains two interviews conderning this subject, one with Prof. Christof von Kalle (from NCT Heidelberg) and one with Dr. Frank Kischkel (TherapySelect). This...